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Antigen presentation is no longer the exclusive domain of cells of hematopoietic origin.
Recent works have demonstrated that lymph node stromal cell (LNSC) populations,
such as fibroblastic reticular cells, lymphatic and blood endothelial cells, not only
provide a scaffold for lymphocyte interactions but also exhibit active immunomodu-
latory roles that are critical to mounting and resolving effective immune responses.
Importantly, LNSCs possess the ability to present antigens and establish antigen-
specific interactions with T cells. One example is the expression of peripheral tissue
antigens, which are presented on major histocompatibility complex (MHC)-I molecules
with tolerogenic consequences on T cells. Additionally, exogenous antigens, including
self and tumor antigens, can be processed and presented on MHC-I complexes,
which result in dysfunctional activation of antigen-specific CD8+ T cells. While MHC-
I is widely expressed on cells of both hematopoietic and non-hematopoietic origins,
antigen presentation via MHC-II is more precisely regulated. Nevertheless, LNSCs
are capable of endogenously expressing, or alternatively, acquiring MHC-II molecules.
Transfer of antigen between LNSC and dendritic cells in both directions has been
recently suggested to promote tolerogenic roles of LNSCs on the CD4+ T cell com-
partment. Thus, antigen presentation by LNSCs is thought to be a mechanism that
promotes the maintenance of peripheral tolerance as well as generates a pool of
diverse antigen-experienced T cells for protective immunity. This review aims to integrate
the current and emerging literature to highlight the importance of LNSCs in immune
responses, and emphasize their role in antigen trafficking, retention, and presentation.
Keywords: lymph node, stromal cells, antigen presentation, cross-presentation, immunomodulation
Abbreviations: APC(s), antigen-presenting cell(s); BEC(s), blood endothelial cell(s); BM, bone marrow; CIITA, class II
transactivator; DC(s), dendritic cell(s); DN, double negative; DT, diptheria toxin; eTAC(s), extrathymic Aire-expressing
cell(s); FDC(s), follicular dendritic cell(s); FRC(s), fibroblastic reticular cell(s); gp38, podoplanin; HEV(s), high endothe-
lial venule(s); IFN-γ, interferon-γ; LEC(s), lymphatic endothelial cell(s); LN(s), lymph node(s); LNSC(s), lymph node
stromal cell(s); LSEC(s), liver sinusoidal endothelial cell(s); MHC(s), major histocompatibility complex(es); OVA, chicken
egg ovalbumin; PLVAP, plasmalemma vesicle-associated protein; PTA(s), peripheral tissue antigen(s); SCS(s), sub-
capsular sinus(es); TAP, transporter associated with antigen processing; TLR(s), toll-like receptor(s); TNF-α, tumor
necrosis factor-α; Treg(s), regulatory T cell(s); VEGF, vascular endothelial growth factor; VSV, vesicular stomatitis
virus.
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Introduction
One of the hallmarks of adaptive immunity is the T cell-antigen-
presenting cell (APC) crosstalk that takes place in lymph nodes
(LNs). As secondary lymphoid organs, LNs are essential in main-
taining tolerance as well as initiating and resolving immune
responses (1). LNs constitute particular locations where periph-
eral tissue environments are sampled in the form of endoge-
nous and exogenous antigens. These processes occur in specific
LN regions and are finely controlled by resident stromal cells
that promote lymphocyte trafficking and maintain lymphocyte
homeostasis.
Lymph node stromal cells (LNSCs) constitute a heterogeneous
mixture of non-hematopoietic cells (CD45 ) ofmesenchymal and
endothelial origins (2), and have long been appreciated to provide
the scaffold on which immune cells encounter antigen (3, 4).
Despite their low frequency (<1% of the LN cell count), recent
studies have elucidated that LNSCs have active and important
roles in shaping the immune response.
The main CD45  LNSC populations can be defined based
on their expression of podoplanin (gp38) and PECAM-1 (CD31)
by flow cytometry (5–7). They include fibroblastic reticular
cells (FRCs: CD31  gp38+), lymphatic endothelial cells (LECs:
CD31+ gp38+), blood endothelial cells (BECs: CD31+ gp38 )
(5, 6, 8) and a less studied double negative population (DN:
CD31  gp38 ). Follicular dendritic cells (FDC: CD21+, CD35+,
FDC-M1+) constitute an additional subset derived from non-
hematopoietic origins (9), which can also express gp38 (5, 10, 11).
These LNSC populations help define and organize the structure of
the LN as a whole, and because of their distinct anatomic localiza-
tions, they can each shape immune responses in complementary
ways.
Within LNs, FRCs form an intricate and highly organized retic-
ular network that not only contributes to lymphocyte trafficking
but also organizes the lymphocyte populations into different func-
tional zones (12). As the FRC network defines the T cell zone in
the cortex, FRCs have been associated with T cell biology. They
are a major source of IL7, which is essential for T cell homeostasis
(5), and additionally are known to be a source of the chemokines
CCL19 and togetherwith LECs, CCL21 (13, 14), which both act on
the homing receptor CCR7 on T cells. Moreover, FRCs contribute
to the regulation of T cell activation by providing a reticular
network that facilitates dendritic cell (DC)–T cell interactions, and
subsequent T cell priming (12, 15–17). At the same time, local T
cell-derived interferon (IFN)-γ and tumor necrosis factor (TNF)-
α act synergistically to induce nitric oxide production by FRCs
through the activation of inducible nitric oxide synthase (iNOS)
(18–20), thus inhibiting T cell proliferation. More recently, FRCs
have been shown to support B cell survival (21).
The lymphatic vascular network, formed by LECs, ensures the
transport of antigens from peripheral tissues to local LNs, and
then to downstream LNs (22). Within LNs, LECs define the floor
and the ceiling of the subcapsular sinus (SCS) and the cortical
andmedullary sinuses. As lymphatic vessels are the primary route
of soluble and APC-carried antigen to the LN, LECs are well-
situated to interact directly with lymph-borne antigens, as well as
LN-resident and migratory DCs (23), via production of IL7 and
CCL21 (24). Under inflammatory conditions, LECs can directly
attenuate DC activation through contact-dependent mechanisms
(25). Moreover, LECs directly influence T cell activation, in part
by dampening activated T cell proliferation through the produc-
tion of nitric oxide (18, 19). LECs also help direct T cell egress from
LNs through secretion of S1P, which is augmented by tenascin-C
interactions with α9-integrin on activated LECs (26–28).
BECs line blood vessels that irrigate LNs. The majority of naïve
lymphocytes enter LNs from the blood and reach the specific
T-cell zones through the specialized high endothelial venules
(HEVs) in the cortex (29). HEVs are known to actively promote T
cell recruitment and ingress into the LNparenchymaby producing
CCL21 (30) and transcytosing CCL19 (31) from the parenchyma.
Specifically located within B cell follicles, FDCs are essential
in defining and maintaining the B cell follicular structure, thus
shaping humoral immunity (32–34). FDCs have been recently
shown to differentiate from marginal reticular cells, which share
surface markers with FRCs, yet represent a distinct LNSC subtype
located primarily near the SCS and B cell follicles (10). FDCs
have a specialized role in maintaining and coordinating B cell
responses, including self-reactive B cell deletion (35).
Together, LNSCs create the framework of the LN,with key func-
tional consequences, including guiding peripheral antigens and
cells into the LN, and regulating the residence time and interac-
tions of lymphocytes andAPCs in the LN (36–38). Immunological
roles of LECs and FRCs have been recently reviewed elsewhere
(24, 39). Here, we focus on how peripheral antigen sampling
and presentation by LNSC may contribute to the overall immune
response.
LNSCs Coordinate Antigen Availability
in the LN
Adaptive immunity is a feature of evolved immune systems and
relies on the ability of lymphocytes to recognize cognate antigens
in the context of a major histocompatibility complex (MHC) (40).
In this regard, there are at least two levels of LNSC participa-
tion in antigen presentation. One is the traffic control of antigen
distribution, involving the spatial and temporal delivery of LN-
infiltrating antigens to specific LN compartments (41). The other
resides in the ability of LNSCs themselves to process and present
antigens directly to T cells (36).
Antigen Traffic Control in the LN
The lymphatic system represents an efficient and sophisticated
mode of communication between peripheral tissues and their
draining LNs, with the lymph as its medium. The lymph is com-
posed of a mixture of biomolecules, including proteins, peptides,
and exogenously derived antigens that reflect the state of the
peripheral tissue. Under normal, physiological conditions, lymph
has been shown to be significantly enriched, relative to plasma,
in intracellular and extracellular matrix proteins and peptides
derived from tissue homeostatic turn-over (42). Human lymph
has also been shown to carry a more diverse self-peptidome rel-
ative to plasma (43). Hence, the lymph fluid appears to represent
a comprehensive status report of the peripheral tissues. Following
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FIGURE 1 | Exogenous antigen distribution in the lymph node is
choreographed by stromal cells. Lymph-borne peripheral exogenous
antigens arrive in the lymph node (LN) via the afferent lymphatic vessels as
fast-draining soluble or slow arriving cell-associated forms. Floor and ceiling
lymphatic endothelial cells (LECs, violet) are the first stromal cells encountered
by the antigens in the subcapsular sinus (SCS). Soluble antigens can be taken
up and sequestered by LECs (a), while the remaining fraction of antigens leave
the SCS: lower molecular weight antigens are channeled to conduits
surrounded by fibroblastic reticular cells (FRCs, ochre) and are filtered through
plasmalemma vesicle-associated protein (PLVAP) diaphragms on floor LECs
(b); immune complexes and particles are ferried across the SCS by SCS
macrophages (Mφ) (c). The bulk of soluble antigens not retained or channeled in
the above compartments pass through to the medullary sinus, where they are
sampled by medullary sinus dendritic cells (DCs) prior to draining to the
downstream LN via efferent lymphatic vessels (d). Floor and ceiling LECs
establish chemokine gradients that guide antigen-bearing migrating DCs arriving
from the periphery by differential expression of atypical chemokine receptors,
such as CCRL1, that scavenge CCL21 (e). In the parenchyma, soluble antigens
channeled in the conduits are sampled by FRCs as well as LN-resident DCs
(f) before they reach the high endothelial venules (HEVs, aqua), which are
surrounded by FRCs or α7+ pericytes (green, part of the double negative DN
stromal population), and enter the circulation where they can be sampled by
blood endothelial cells (BECs, aqua) (g). Conduits also deliver lower molecular
weight antigens to follicular dendritic cells (FDCs, rose) in the B cell follicle
(h), while SCS Mφ relay larger antigens to FDCs or to B cells (i). Antigens on
FDCs are available for sampling by DCs and antigen-specific B cells for
extended durations. Stromal cells as well as APCs communicate with T cells,
contributing to antigen-specific immunological outcomes.
an infection or an inflammatory challenge, exogenous antigens
and self-peptides from damaged cells, together with homeostatic
components of lymph, enter tissue-draining LNs. This mixture of
antigens, including soluble, particulate, and APC-borne forms, is
ushered to different anatomic regions of the LN, notably through
the interaction with resident LNSCs (Figure 1).
LN Entry of Soluble Antigens
Soluble molecules in the lymph enter LNs and are immediately
subjected to size-based sorting. Much of our understanding of
soluble antigen entry into LNs comes from intravital microscopy
studies focused on understanding the generation of humoral
immunity (44–47). Upon entry into the SCS, lower molecular
weight antigens (.70 kDa) are immediately channeled to FRC-
lined conduits entering the B cell follicles (17), allowing for direct
cognate B cell (48) as well as FDC (49) sampling in the folli-
cles, which are important steps toward a humoral response. SCS
macrophages (50) and DCs surrounding HEVs (51) also sample
antigens. In addition, low molecular weight proteins can also be
rapidly sampled by DCs in the LN to elicit T cell responses (52).
Meanwhile, a bulk of the remaining, unsampled low molecular
weight antigens will end up exiting through HEVs to reach the
circulation, or alternatively, through efferent lymphatic vessels,
which feed into the next LN (53, 54).
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Larger molecules (&70 kDa) lag behind the small molec-
ular weight antigens by several minutes following LN entry
and may take hours to reach cognate B cells (48). This size-
dependent distribution and retention time in the LN is in part
due to sieve-like diaphragms, composed of plasmalemma vesicle-
associated protein (PLVAP) in the SCS LECs (55). PLVAP was
originally identified as a BEC-specific molecule that regulates
vessel permeability and was recently shown to be important for
the formation of fenestrae in liver sinusoidal endothelial cells
(LSECs), enabling the regulation of macromolecular transport in
the liver (56). In LNs, PLVAP co-localized with the subcapsu-
lar and medullary sinus-lining LYVE-1+ LECs as well as HEVs
(55). PLVAP-deficient mice exhibit an increased permeability of
180 kDa proteins and 500 kDa dextran into the LN parenchyma
through the FRC conduits. These observations emphasize the
importance of PLVAP in size-based mechanical filtration of anti-
gens in the LN sinus. As a result, larger molecules are gener-
ally excluded from the cortex and are forced to pass through
the LEC-lined medullary sinuses to drain to the next LN. As
a result, these larger molecules pass through an environment
rich in LN-resident DCs (sinusoidal DCs) that extend protru-
sions into the medullary sinus to actively sample the lymph
(57). The size-exclusion properties of the LNSC architecture
seems to be maintained during inflammatory LN remodeling, as
was observed in the case of intradermally administered vaccinia
virus (53).
LN Trafficking of Particles
Aside from soluble antigens, cell-free antigens can come in the
form of particulates, including exosomes, microvesicles, apoptotic
bodies, and othermembrane-bound particles arising from steady-
state and inflammatory conditions (58). Viruses and bacteria, lipid
macrostructures, such as alpha-GalCer, and synthetic particles
generally occur within a similar size range (59), and are promptly
intercepted by the SCS macrophages upon LN entry (57, 60–67),
although this capture does not always translate to the development
of humoral immunity (63).
Immune complexes, which consist of antigens coated with nat-
ural or antigen-specific antibodies and complement proteins, may
also behave like “particles” (68). The captured immune complexes
are then relayed either directly or alternatively via complement
receptor-expressing naïve B cells to FDCs (69, 70).
The remaining unsampled particulates bypass the LN cortex
and flow directly to the LN medullary sinus, where they may be
captured by LN-resident sinusoidal DCs in a similar fashion as
described earlier for the large soluble antigens. Particulate anti-
gens, ranging from 40 nm up to at least 1μm in diameter were
shown to be captured by the sinusoidal DCs (57). This pattern
of particles captured in the medullary sinus is consistent with
what has been observed for other particulate antigens (63, 71).
Furthermore, it has been shown to be essential for the timely
generation of both CD4+ and CD8+ T cell responses to particle-
conjugated OVA, while immune responses against soluble antigen
developed independently of this mechanism (57).
Thus, while lymphatic transport of larger particulates from the
periphery may not be as efficient as that of soluble antigens (72),
LNSCs indirectly improve the timeliness of T cell responses by
contributing avenues that promote rapid routing of particles in the
size range of pathogens to LN-resident sinusoidal DCs.
Cell-Associated Antigens in the LN
Antigens may also be carried to the draining LN by peripheral
APCs. The trafficking of APCs from the periphery to the LN
has been extensively studied (22, 73, 74). In this process, LECs
play an important role by promoting APC entry into lymphatic
vessels (75–77) and regulating their intra-lymphatic motility (76–
78) even when only partial dermal lymph drainage is available
(79). In areas of inflammation, inflammatory signals and changes
in interstitial fluid drainage into local lymphatic vessels promote
DC recruitment and transmigration in several ways. Following
binding of immune complexes, DCs become more responsive to
recruitment via gradients of CCL19 (80). Inflammatory signals
can also increase LEC expression of the adhesion molecules,
ICAM-1, VCAM-1, and E-selectin, upregulate CD137 (4-1BB)
and CCL21 secretion, and promote CX3CL1 (fractalkine) shed-
ding (81–85). Altogether, these phenotypic changes in LECs and
DCs coordinate increased DC transmigration into lymphatic ves-
sels and into draining LNs, in which direct interactions between
LECs and DCs are required for efficient DC migration into the
LN (86).
While the effects of peripheral lymphatics on DC motility are
well documented, the influence of LN-resident LNSC on DC
motility is less well known. DC entry into the LN is driven by a
chemokine gradient generated by LECs (14). In the subcapsular
space, LECs on the afferent side (ceiling LECs) but not on the floor
of the capsule (floor LECs)were shown to reduceCCL21 levels due
to the expression of atypical chemokine receptor, CCRL1. Such
atypical chemokine receptors bind their ligands but fail to signal
(87, 88). More importantly, the scavenger function of CCRL1 led
to the generation of a localized CCL21 gradient that prompted
the entry of DC into the LN parenchyma. In addition to CCRL1,
CCL21has other binding partners, such as podoplanin (89), which
may also contribute to the modulation of DC-mediated antigen
transport. LNSCs have been shown to partake in intra-LN control
of chemokine distribution by other atypical chemokine receptors,
such as D6 on afferent LECs and HEVs (90, 91), and Duffy
antigen receptor for chemokine transcellular transport (DARC)
onHEVs (92). In the LN, binding of CLEC-2 onDCswith gp38 on
FRCs, but not LECs, has been demonstrated as a key axis for DC
movement (77, 93). Inflammation seems to coordinate CLEC-2
and gp38 expression, which provides an explanation for enhanced
interaction between DCs and FRCs (11, 77, 94). By modulating
the recruitment of antigen-loaded DCs from peripheral tissues
into and within the LN parenchyma, LNSCs help specify the
location and duration of cell-borne antigen availability in the LN.
Further studies to understand these DC-stromal cell interactions
at a molecular level will likely reveal additional insights on the
stromal functions in the LN.
LN Antigen Retention
Antigen retention is a way of modulating antigen availability
during an immune response. Indeed, LNSCs have been known to
be safe havens for some pathogens (4, 33). LNSCs are infection
targets in some experimental settings, as described for FRCs in
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a mouse model of persistent lymphocytic choriomeningitis virus
(LCMV clone 13) infections (95, 96). The chronicity of the viral
burden is sustained in part by upregulation of PD-L1 in infected
FRCs that counteract the antiviral CD8+ T cell response.
In addition, during acute infections or after vaccination, LECs
have been described as antigen reservoirs. Antigen archiving
required the induction of LEC proliferation, which, in turn, was
an effect of non-cognate T cell proliferation. These observations
suggest that T cells can indirectly prolong the persistence of virally
derived antigens after the clearance of the virus by promoting
antigen archiving function in LECs, which translated to protective
memory in the CD8+ T cell compartment (97).
Antigens derived from apoptotic cells as well as pathogens are
known to be retained in LNs by FDCs (33). FDCs retain antigens
on FcγRIIb inhibitory Fc receptors andCD21/CD35 (complement
receptors Cr2/Cr1) for presentation to cognate B cells (32, 98,
99). Binding to any of these receptors results in rapid internaliza-
tion of the immune complexes (100, 101). However, rather than
continuing onto a degradation pathway, the engaged complement
receptor 2 (Cr2) undergoes periodic recycling and the untam-
pered antigen is therefore made available on the FDC surface
over an extended period (100). Immune complexes on FDCs can
then be sampled by LN-resident DCs to be presented on MHC-
I and II with demonstrated deletion of antigen-specific CD8+
T cells (102). Whether other LNSC utilize a similar, recycling,
non-degradative compartment remains to be seen. Neither CD21
nor CD35 have been reported to be expressed on other LNSCs
(Figure S1 in Supplementary Material), making FDCs unique in
this mode of prolonged, intact antigen presentation.
It must be remarked that many studies that discuss anti-
gen uptake and persistence often overlook LNSCs. For example,
studies demonstrating particulate antigen capture by CD169+
macrophages do not routinely counter-stain for LECs with
LYVE-1. However, intradermally injected vesicular stomatitis
virus (VSV) results in significant internalization by LYVE-1+
cells, regardless of macrophage depletion by clodronate lipo-
somes (61). Similarly, few dynamic imaging studies investigating
antigen-specific responses in the LN marked the stroma (12),
precluding the opportunity to study the participation of LNSCs.
On these grounds, there is a need to clearly define and place
LNSC contributions within the current understanding of antigen
availability in the LN.
Structure–Function Relationships in LNSCs
Govern Antigen Availability and Influence
Immune Responses
The crucial role of LNSCs in coordinating antigen availability and
presentation kinetics of APCs in the LN (3) has been illustrated in
a number of inducible knockout models (Table S1 in Supplemen-
taryMaterial). Removing specific LNSC subsets has been achieved
in different experimental conditions by expressing the diphtheria
toxin (DT) receptor in FDCs (Cd21-Cre) (32), FRCs (Ccl19-Cre,
FAP) (103, 104), and LECs (Lyve1-Cre) (105). The absence of any
of these LNSC subsets was expectedly sufficient to severely disrupt
LN compartmentalization and lymphocyte numbers, leading to
an impaired immune response. FDC-depleted LNs cannot retain
immune complexes and exhibit deficiencies in germinal center
responses (32, 106). Selective depletion of FRCs resulted not only
in a deficient T cell response but also correlated with a dramatic
reduction of the B cell chemoattractant molecule CXCL12 and the
pro-survival factor BAFF, accompanied by follicle destabilization
and impaired germinal center formation (103). FRCs appear to
regulate the trafficking of mainly naïve lymphocytes as FRC-
depleted mice responded to inflammatory challenge with similar
numbers of effector T andB cells to normal controls (104). TheDT
depletion approach was less informative when applied to LECs.
In a mouse model where DTR expression is induced in LYVE1+
cells, systemic DT administration depleted LYVE1+ cells in the
intestinal–blood barrier, leading to sepsis (105).
In these depletion studies, lymph and thus antigen flow from
the periphery and in the LN is partially maintained. Diminished
lymphatic drainage is known to perturb LN B cell organization
and humoral immunity (107, 108). However, even when lym-
phatic drainage is retained, the absence of LNSCs has conse-
quences. Despite the remaining flow of lymph through the ghost
FRC conduits, it becomes clear that not only FDCs but also FRCs
are indispensable for organizing the boundaries of B cell follicles
and the humoral response. This is reflected in the fact that Notch
signaling in FRCs has been shown to be important for T follicular
helper cell differentiation and germinal center formation (109).
This example highlights the synergistic effects of multiple LNSC
subtypes and different pathways toward the humoral response,
and is likely responsible for regulating the number of B-cell fol-
licles per LN, which otherwise generally scales with the LN size
under homeostatic conditions (110).
Another example of synergy between LNSC subsets has been
described, where FRCs support the expansion of LECs and BECs
by expressing vascular endothelial growth factor (VEGF) and
other molecules (8, 111), aided by LN-resident CD11c+ cells
(112). In addition to supporting the expansion of other LNSC sub-
sets, under inflammatory conditions, the gp38-CLEC-2 signaling
axis between FRCs and DCs results in LN structural relaxation by
decreasing the contractility of FRCs, ultimately creating space to
accommodate increased cell numbers in the LN (113, 114). This
pathway is also important in the maintenance of HEV structural
integrity as CLEC-2 on platelets can signal through gp38 on FRCs
that surround HEVs (115).
In this regard, it is of notable importance that antigen capture,
MHC processing, and T cell activation by LN-resident DC are all
spatially linked processes (57). While peripheral DC migration
to the LN is necessary for a robust immune response, in part by
prolonging the time frame of antigen availability within the LN
(52, 116), the lymphatic sinus DCs were found to be sufficient to
elicit both antigen-specific CD4+ and CD8+ T cell responses as
well as T follicular helper responses, leading to humoral immu-
nity (57). This suggests that antigen drainage and capture occur
immediately, triggering an early adaptive immune response and
migratory DCs act to amplify the response later upon their arrival
to the T cell zone (23). Thus, APC distribution in the LN and their
spatial signature (23) affect the kinetics of the immune response.
LNSCs are essentially upstream of this process, and in turn,
are significantly involved in channeling antigens into the correct
subanatomic locations so as to modulate antigen availability to
various APC subpopulations.
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Taken together, functional lymph flow, antigen sorting, and LN
structural integrity maintained by LNSCs are important for the
generation of adaptive immune responses. These aremanifested in
the dynamic LNarchitecture, which in turn affects the kinetics and
time scale of B andT cell activation, proliferation, and polarization
as well as feeds back to alter the LN structure and prolong antigen
availability.
Direct Antigen Presentation by LNSCs
There is a growing appreciation that LNSCs not only guide the
antigens to APCs but also that they themselves present antigen to
educate T cells.
Brief Introduction to Antigen Presentation
Typically, antigen-presentation pathways are introduced in such a
way that intracellular antigens are presented to CD8+ T cells as
peptide:MHC-I complexes, while extracellular antigens are pre-
sented to CD4+ T cells as peptide:MHC-II complexes. Presen-
tation of self-antigens by MHC-I on all nucleated cells prevents
attack by effector CD8+ T cells (117). At the same time, MHC-I
presentation allows the presentation of intracellular pathogen-
associated epitopes for elimination of infected cells. On the other
hand, the processing of extracellular antigens for MHC-II presen-
tation to activate CD4+ T cells had been conventionally thought
to be restricted to professional APCs. Upon internalization, the
extracellular antigens in the trafficking vesicle remain topolog-
ically outside while they are processed to generate peptides for
MHC-II loading (118, 119). However, neither topological segre-
gation of antigens on the level of the APC nor the exclusivity
of certain antigen-presentation pathways to professional APCs
captures the full story of MHC-I and MHC-II presentation.
With regards to antigen presentation on MHC-I, it is clear that
intracellular antigens from cytoplasmic or intranuclear sources
are processed by the proteasome and other cytosolic proteases in
the cytoplasm, imported into the endoplasmic reticulum by the
transporter associated with antigen-processing (TAP) complex,
trimmed, and loaded onto MHC-I. The MHC-I model must also
account for exogenous antigens, such as self-antigens draining
to the LN under homeostatic conditions, which are presented
on MHC-I, the well-known phenomenon of cross-presentation
(120). In this process, exogenous antigens leave endocytic vesicles
to access the cytoplasmic space for processing and loading onto
the MHC-I presenting machinery in a TAP-dependent manner in
the endoplasmic reticulum (121–123) or in phagolysosomes (124,
125). Alternatively, exogenous antigens can be loaded ontoMHC-
I molecules within recycling vesicles in a TAP-independent man-
ner (126, 127). The importance of the cross-presentation pathway
can be appreciated in that tumors (aberrant self), and intracellular
pathogens (non-self) either lose, or have evolved mechanisms to
prevent MHC-I antigen presentation, to evade cytotoxic T lym-
phocyte (CTL) destruction of tumors, or pathogen-infected host
cells, respectively (128, 129). This antigen-processing pathway,
previously thought to be the domain of professional APCs, has
now been described for other cell types (130).
With regards to MHC-II presentation, phagocytosis and pro-
cessing of extracellular antigens eventually leads to peptides that
are loaded onto MHC-II mainly in MHC-II-enriched multivesci-
cular compartments (131, 132). For epitope peptides to bind to
MHC-II, the MHC-II chaperone invariant chain (Ii) must first
be cleaved to Class II-associated invariant chain peptide (CLIP).
CLIP is then released by the enzyme H2-M to bind the MHC-II
epitope peptides for the peptide:MHC-II complex to finally be
available on the APC cell surface (133). Interestingly, these pro-
teins involved in MHC-II presentation are not completely absent
from LNSCs on the transcription level (8, 134, 135) (Figure S2 in
Supplementary Material).
In addition, MHC-II can be loaded with intracellular antigens
as suggested by the analysis of MHC-binding peptide repertoire
in the thymus (136, 137). Autophagy and endocytosis of apoptotic
material can introduce intracellular antigens to the MHC-II path-
way (136). Again, existence of viral evasion mechanisms suggests
the importance of this pathway (138).
Other intracellular pathways are shared for both MHC-I and
-II loading, such as the gamma-interferon-inducible lysosomal
thiolreductase (GILT) enzymes in DCs (139), which are thought
to aid in antigen translocation into the cytosol (MHC-I) as well as
exposure of buried epitopes (MHC-II) (140).
These observations demonstrate that antigen presentation is
not limited by the topological origins of the antigen and that
antigen presentation pathways previously thought to be restricted
to professional APCs can be active in other cell types. As such,
both self- and non-self-antigens can be presented on MHC-I and
MHC-II molecules. The antigenic self-peptide repertoire is highly
plastic (141), and may be changed under inflammatory condi-
tions with the induction of the immunoproteasome (142, 143) or
altered MHC trafficking in activated DCs (133). Finally, antigen-
presentation capacity is variable in efficiency and duration as well
as environmentally modulated in different DC subsets (144). This
opens the possibility for antigen presentation by LNSCs to partake
in the modulation of the immune response.
MHC-I Presentation by LNSCs
MHC-I Expression in LNSCs
Nearly all nucleated cells constitutively express MHC-I, LNSCs
being no exception. The MHC-I complex at the cell surface con-
sists of a polymorphic MHC-I together with a non-polymorphic
β2microglobulin (β2M), both of which are regulated by a specific
transactivator NLRC5 (145).MHC-I expression can be induced in
response to IFN-γ through the IFN-stimulated response element.
This upregulation of MHC-I was observed when LNSCs were
in the presence of toll-like receptor (TLR) agonists, or engaged
in an antigen-specific interaction with T cells (146–148). Along
with MHC-I expression, NLRC5 induces TAP1 and LMP2 (pro-
teasome subunit β type 9), coordinating the expression of some
main proteins involved in the cytoplasmic antigen-processing and
MHC-I-presentation pathways.
Self-Antigen Expression in LNSCs
Peripheral tissue antigens (PTAs) can be promiscuously expressed
in the thymus in medullary thymic epithelial cells for the pur-
pose of negative selection of T cells in central tolerance (149).
However, some self-reactive T cells remain in the periphery (150,
151). Tissue draining, but also non-draining, LN FRCs, LECs, and
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BECs have been described to express PTA repertoires, including
both endogenous PTAs as well as transgenically introduced PTAs
(146, 152–155). Interestingly, these repertoires are not overlap-
ping between the LNSC subsets (146, 156), likely attributable
to differential expression of transcription factors driving PTA
expression, such as Autoimmune regulator (Aire) (146, 154) and
deformed epidermal autoregulatory factor 1 (Deaf-1) character-
ized in the pancreatic LN (157). Within a LNSC subset, PTA
expression can further be localized subanatomically (156). For
example, in the LN, the PTA Tyr369 is presented only by the
medullary LECs as evidenced by antigen-specific CD8+ T cell
proliferation, when LN LECs were separated into subcapsular,
medullary, and cortical LECs based on the differential expression
of MAdCAM-1 and PD-L1 (156). The intracellular mechanisms
of PTA MHC-I presentation have not been addressed in any of
these studies, though it is assumed to be the same as with any
endogenously expressed intracellular antigen.
The PTA expression pattern in the mouse suggests that the LN
is particular in the presentation of antigens by stromal cells. In
the spleen, another important secondary lymphoid organ, stromal
cells did not express detectable PTAs compared to LNSCs (152,
153). Moreover, the same stromal cell types in the periphery
express fewer PTAs than those in the LN. For example, unlike
their LN counterparts, LECs isolated from the diaphragm and
colon cannot present the PTA Tyrosinase to antigen-specific T
cells (156).
Whether there exist overarching drivers or triggers for the LN-
restricted expression of PTAby LNSCs, and how this is subdivided
into specific cell types in subanatomic locations, has not yet been
explored.
Exogenous Antigen Cross-Presentation in LNSCs
As polarized cells with active endocytotic and transcytotic path-
ways, LNSCs actively take up exogenous molecules and some
subsets process antigens for cross-presentation and cross-priming
of antigen-specific CD8+ T cells. This was confirmed in several
models using OVA as a model exogenous antigen, as detected by
the 25d1.16 antibody, which recognizes the MHC-I epitope of
OVA complexed withMHC-I, SIINFEKL:MHC-I, on APCs. OVA
derived fromOVA-expressing B16F10 tumorswas found to be dis-
played onMHC-I in LECs in the tumor and the draining LN (158).
Similarly, SIINFEKL:MHC-I complexes were confirmed on LECs
incubated with synthetic nanoparticles bearing OVA-derived long
peptides in vitro (148, 158). In these studies, OVA-loaded primary
LN LECs were shown to be capable of cross-priming OT-I CD8+
T cells in a TAP1-dependent manner (148).
For LN FRCs, FDCs and BECs, on the other hand, no intracel-
lular antigen-processing pathways have been described. However,
cross-presentation by BECs has been described in other organs.
Primary cultures of murine aortic BECs have been shown to
cross-present exogenous male antigen to a T cell hybridoma cell
line MHH, specific for the MHC-I (Db) restricted male antigen
HYUty (159). LSECs also present exogenous antigen in a TAP1-
dependent manner (130, 160, 161). This suggests that LN BECs
may also cross-present exogenous antigens on MHC-I.
Active exogenous antigen (protein and particle) uptake and
degradation, a necessary upstream process for exogenous antigen
presentation including cross-presentation, has been documented
in LNSCs. In addition to protein and particle uptake by LECs
in vitro (147, 148), fluorescently labeled OVA has been detected
in LYVE-1+ LECs within minutes of intradermal injection in vivo
(148). In a similar study, intracellular antigen degradation and
processing was visualized by increased DQ-OVA fluorescence
within 90min of subcutaneous injection (17). A recent report
suggested that LECs can retain antigen over extended time peri-
ods, with detectable OVA fluorescence in LECs even at 1–3weeks
after injection. However, the same report also described that
DQ-OVA fluorescence, delivered with TLR agonists and anti-
CD40, was no longer detectable in LNSC populations by flow
cytometry a week after injection (97). This suggests that more
than one pathway of OVA uptake or intracellular trafficking is
active in LECs such that ingested antigens may be trafficked
and processed differently when antigen reaches the cells together
with inflammatory signals, such as TLR agonists and anti-CD40
(162–164).
Such feedback mechanisms where the composition of an
ingested antigen influences antigen trafficking are known to exist
on professional APCs. Scavenging receptors can bind to antigens
associated with heat shock proteins and other chaperone proteins,
with resulting cross-presentation of the antigen (165, 166). They
can also interact with TLRs, and affect the immunological phe-
notypes of APCs, such as the polarization of macrophages (167).
Engagement of one such receptor, the mannose receptor, has
been shown to route the binding antigen to a cross-presentation
pathway (168). Further facilitating MHC-I processing, subse-
quent ubiquitination of mannose receptor can lead to cytoplasmic
escape of the mannose receptor bound antigen, enabling easier
access to MHC-I loading machinery (169, 170). Although cross-
presentation, involving these mechanisms, has been shown thus
far in model cell lines and in DCs, it cannot be ignored that the
majority of the scavenger receptor superfamily (167), other known
cross-presentation receptors, and C-type lectins are abundantly
expressed by skin draining and mesenteric LNSCs (Figure S1 in
Supplementary Material). Together with their expression of other
proteins important in cross-presentation and a number of TLRs
(146) (Figure S1 in SupplementaryMaterial), the existence of these
scavenging pattern recognition receptors (PRRs) on LNSCs may
play a role in the cross-presentation of exogenous antigens, thus
shaping immunological outcomes.
While the importance of scavenging receptors on LNSC
immunobiology is only beginning to be appreciated, their gene
expression patternmay help explain the preferential accumulation
of the intradermally administered OVA in LECs versus in other
LNSCs (97, 148). This LNSC distribution is somewhat unexpected
because OVA is a low molecular weight protein (45 kDa), and
therefore FRC and BEC association would follow the expected
drainage pattern (Figure 1). However, because OVA is man-
nosylated (171), this may preferentially drive internalization by
mannose receptor CD206 (172), which amongst the LNSCs, is
present only on LECs (Figure S1 in SupplementaryMaterial). This
phenomenon may also be mirrored in the uptake and persistence
of Herpes Simplex Virus glycoprotein in LECs (97), as baculovirus
production of antigens can result inN-glycanswith high-mannose
glycosylation patterns (173).
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There are also a number of other major cross-presentation
pathways that have yet to be investigated, and appear to playminor
roles in LNSC. Although it has been shown that DCs efficiently
cross-present immune complexes upon rapid internalization by
Fcγ receptors (174–176), LNSCs do not seem to express high levels
of activating nor inhibitory Fcγ receptors (Figure S1 in Supple-
mentary Material). The one exception is FcRn, which is expressed
across all LNSC. Better known for its IgG recycling and transport
functions in neonatal (177, 178) and drug delivery contexts (179),
FcRn binds to IgG Fc and albumin in acidic environments and
regulates their homeostatic levels in the circulation (180). FcRn
also binds antibody-coated antigens, which has implications in
antigen recycling, antigen archiving, MHC-II presentation as well
as MHC-I presentation (175, 181). Another example involves the
complement receptors, which are constitutively active in profes-
sional APCs, but are largely absent in resting LNSCs. However,
C1q receptor for phagocytosis (C1qrp) stands out as an exception
(Figure S1 in Supplementary Material). In professional APCs,
C1q has been suggested to favor cross-presentation as seen by
priming of antigen-specific T cells, but the direct involvement
of C1q receptor in this process was not demonstrated (182).
Given that multiple C1q-binding partners are known (183, 184),
the functional utility of C1q receptor on LNSCs remains to be
clarified.
Whether any of these transcriptional findings of antigen scav-
enging receptor genes on resting state LNSCs have productive
functions in antigen presentation is an open question. In addition,
the efficacy of cross-presentation mainly studied in professional
APCs depends on physical properties of the antigen (162, 185,
186). Furthermore, uptake mechanisms can determine the fate of
the internalized antigen in one of the several trafficking pathways
depending on the APC type and the concurrent inflammatory
signals (163). These mechanisms are only beginning to become
elucidated in LNSCs. Nevertheless, it is clear that more work
needs to be done to understand the cross-presentation pathways
in LNSCs.
Consequences of Direct MHC-I Presentation by LNSC
One of the most important hypotheses to describe the activa-
tion of CD8+ T cells involves a three-signal mechanism, which
stipulates that naïve cells will need to (1) recognize their cog-
nate antigen presented in the context of an MHC-I molecule,
(2) receive a co-stimulatory signal through their co-stimulatory
receptors, and (3) be primed by cytokines (187). The impact of
the first signal, direct MHC-I presentation with LNSCs playing
the role of APCs, has been extensively reviewed in the recent
years (1, 24, 36, 155, 188–196). To summarize, peptide:MHC-I
complexes on LNSC surfaces resulted in initial antigen-specific
CD8+ T cell proliferation in all of the models used. Following
the hypothesis, antigen presentation alone without the second
signals – signaling through co-stimulatory receptors – will not
lead to fully functional T cell activation. Notably, these second
signals are lacking in LNSCs (Figure S3 in Supplementary Mate-
rial), which have a negligible level of expression of co-stimulatory
molecules compared toDCs. Furthermore, LNSCs do not upregu-
late the co-stimulatory molecules CD40, CD80, and CD86 follow-
ing stimulation with inflammatory cues, for example, following
TLR engagement (most studies have used TLR3 agonist polyI:C),
or in presence of IFN-γ or TNF-α (18, 146–148, 197).While LECs
upregulate the immunostimulatory molecules HVEM, CD48, and
MHC-II under such conditions (197), they also concomitantly
upregulate PD-L1, as do FRCs, and BECs under the same inflam-
matory conditions (146, 148, 197, 198). Such observations explain
findings, describing the early generation apoptosis of antigen-
specific CD8+ T cells following co-culture with antigen-loaded
LEC in vitro (148, 197). Furthermore, LEC-educated CD8+ T
cells express less IFN-γ or IL2 than DC-educated counterparts,
and cannot be reactivated by the addition of IL2. In vivo LNSC
antigen-presentation studies have also reported poor recovery of
transferred antigen-specific T cells (135, 146, 152–155, 158), due
to inhibitory LNSC-CD8+ T cell crosstalk via the PD-L1:PD-1
andMHC-II:LAG3 (135) signaling axes. Thus, with the exception
of one report using a model of PTA expression (134), most studies
have suggested that direct antigen presentation by LNSCs, specif-
ically by LECs and FRCs, appears to promote a dysfunctionally
activated phenotype in interacting CD8+ T cells, which can result
in deletional tolerance.
MHC-II Presentation by LNSC
The hallmark of professional APCs, namely DCs, macrophages,
and B cells, is the constitutive cell surface presence ofMHC-II and
their proven ability for antigen processing and presentation (133).
Constitutive MHC-II expression is restricted to a small number
of cells of the immune system. Nonetheless, as reviewed recently
(199, 200), there are now many different cell types from both
hematopoietic and non-hematopoietic origins that can indeed
express MHC-II and interact with CD4+ T cells in the periphery.
MHC-II Expression by LNSCs
LNSCs constitute such non-professional APC cell types that
express MHC-II. Unlike MHC-I molecules, however, MHC-II
expression is highly regulated. The class II transactivator (CIITA)
is the master regulator for the expression of MHC-II. This tran-
scription factor forms a DNA-binding multiprotein complex that
controls MHC-II expression in all MHC-II expressing cell types
(201). CIITA expression itself is regulated by cell-specific pro-
moters, of which three have been identified, namely pI, pIII, and
pIV. Amongst them, the promoter pIV is essential for driving
constitutive CIITA expression in thymic epithelial cells and for
mediating IFN-γ-dependent MHC-II expression in cells of non-
hematopoietic origin, such as endothelial cells, epithelial cells,
fibroblasts, and astrocytes (202). Although MHC-II expression in
human umbilical vascular and foreskin endothelial cells can be
induced by lymphocyte adhesion in a CIITA-independent fashion
(203–205), recent evidence demonstrates the major role of pIV-
driven CIITA for MHC-II regulation in LNSCs.
The first observation of MHC-II expression on endothelial
cells was reported more than 30 years ago (206). The capacity
of human blood and lymphatic endothelia to express MHC-
II was believed to be linked to cytokine stimulation via IFN-
γ or TNF-α (207–209). For example, MHC-II expression on
an immortalized murine FRC cell line also depended on IFN-γ
(210). In recent studies, it was demonstrated that BECs, but not
LECs from skin explants, constitutively expressMHC-II, revealing
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functional differences prompted by environmental factors (211).
Even more recently, steady-state MHC-II expression in LN LECs,
BECs, and FRCs has been reported at both transcriptional and
protein expression levels (8, 91, 134, 147). By using transgenic
mousemodels lacking the different CIITA promoters, steady-state
levels ofMHC-II molecules on the surface of LNSCs were demon-
strated to be a combination of IFN-γ-inducible, pIV-driven CIITA
basal activity, and acquired MHC-II complexes from DCs (198).
In vivo, LNSCs from CIITA pIV /  mice and IFN-γ receptor-
deficient mice exhibit an identical MHC-II profile that was
above background levels, pointing to other contributions. This
suggests that differences in MHC-II expression levels observed
in published studies may arise from environmental factors, for
example, from differences in animal facilities. In addition to
endogenous pIV-mediated MHC-II expression, LNSCs are capa-
ble of acquiring MHC-II from DCs as demonstrated in irradiated
MHC-II-deficient mice re-constituted with MHC-II-expressing
bone marrow (BM) precursors. In these studies, radioresistant
MHC-II-deficient LNSCs displayed significant levels of surface
MHC-II molecules compared to LNSCs in mice re-constituted
withMHC-II-deficient BM. This is supported in vitro by observa-
tions that following removal of hematopoietic cells, LEC and FRC
cultures lack any expression of MHC-II unless co-cultured with
DCs. In vivo, manipulation of DC numbers in LNs significantly
affects levels of MHC-II expressed by LECs, BECs, and FRCs,
demonstrating the existence of intercellularMHC-II transfer from
DCs to LNSCs in vivo.
Antigen Transfer and LNSCs in Antigen-Specific
CD4+ T Cell Responses
Antigen transfer can occur as a peptide exchange on cell sur-
faces as well as the transfer of peptide:MHC complexes through
membrane exchange between cells.
In peptide exchange, peptide epitopes can bind directly on cell
surface or early endosomal MHC molecules (212–216), where
both MHC-I and II are receptive to binding lymph-borne pep-
tides. This is particularly relevant as recent analysis of the human
lymph peptidome showed a predominantly self-peptide reper-
toire, including products deriving from extracellular processing
of proteins, rather than that of the traditional repertoire derived
from intracellular MHC-II processing (43, 217–220). While these
peptides have not been shown to actually bind to LNSCs, these
cells are ideally localized to fully sample these low molecular
weight peptides.
Membrane exchange between cells is not an uncommon occur-
rence in biology and immunology (221). In the LN, for example,
blebs of CD169+ macrophages are acquired by innate-like T cells
and NK cells under steady-state conditions (222). Peptide:MHC-
I and MHC-II complexes have been shown to be transferred
between DC and tumor cells (223) as well as between DCs (224).
In another example,MHC-II has been demonstrated to be present
on exosomes secreted by DCs (225, 226).
Between hematopoietic APCs and LNSCs, transfer of antigens
and peptide:MHC-II complexes seems to play an important role
in MHC-II restricted antigen presentation. Exosomal transfer
appears to represent a major route of MHC-II transfer from pro-
fessional APCs to LNSCs. While FDCs are not able to synthesize
MHC-II themselves (227) nor phagocytose antigens (228), human
tonsillar FDCs have been reported to retain exogenous MHC-II
vesicles (229). By immunoelectronmicroscopy, they were thought
to be exosomes due to their protein immunoreactivity, and were
possibly peptide loaded. While the source of the exosomes was
not clarified (B cells or DCs), suchMHC-II peptide complexes on
FDC cell surface can interact with CD4+ T cells. Exosomes were
also implicated in the transfer of peptide:MHC-II complexes from
DCs to LNSCs (198). The transfer of peptide:MHC-II complexes
from DCs, but not from B cells or macrophages, maintained the
steady-state levels of MHC-II on FRCs, LECs, and BECs (198).
Consistent with known surface marker expression patterns on
LNSCs, if the transfer of DC co-stimulatory molecules occurred,
it did not result in detectable forms.
Antigen transfer between LECs and DCs is however, not
restricted to one direction. Indeed, the transfer of transgenic LEC-
specific PTA to hematopoietic cells has been described (135).
Neither membrane-bound nor cytoplasmically expressed PTAs
were presented by LECs to prime antigen-specific CD4+ T cell
responses (135). This was attributed to the orders of magnitude
lower expression of H2-M in LECs compared to professional
APCs, which is required to free the MHC-II groove for peptide
binding. Instead, the model PTA β-gal expressed by LECs was
shown to be loaded onto MHC-II in hematopoietic cells (135).
While the exchangemechanism is still open to examination, it was
reported not to be dependent on recognition of apoptotic cells or
DC phagocytosis. On the other hand, FRCs and BECs express the
adaptor molecule H2-DM under steady-state and upon inflam-
mation (8, 134) (Figure S2 in Supplementary Material). Despite
this key difference, it remains unclear whether FRCs or BECsmay
act solely as PTA reservoirs or, in addition, can directly present
antigen and impact CD4+ T cells. Supporting direct CD4+ T cell
priming by FRCs, the aforementioned immortalized FRC cell line
was shown to induce CD4+ T cell proliferation in vitro (210).
These complementary bidirectional observations highlight
the close relationship and communication between professional
APCs and LNSCs to enable MHC-II presentation by LNSCs.
As the nature and regulation of MHC-II expression in LNSC
has only recently begun to be elucidated, the functional contri-
butions of LNSC antigen presentation to CD4+ T cells remain
unclear in part due to its complexity. Lack of measurable pro-
ductive T cell responses has been one of the major difficulties
preventing the clarification of the impact of antigen presenta-
tion by LNSCs on CD4+ T cell outcome. As for CD8+ T cell
responses, the absence of co-stimulatory signals, such as CD80 or
CD86 and the constitutive expression of PD-L1 by LNSCs (197,
198), preclude the possibility of functional effector CD4+ T cell
priming. In other words, MHC-II expression is mandatory but
not sufficient to elicit a measurable CD4+ T cell response. In
this regard, it has been shown that human LN-derived LECs fail
to induce allogeneic CD4+ T cell proliferation even after IFN-
γ stimulation (147). In these particular in vitro settings, LECs
were unable to induce proliferation of either naïve or memory
CD4+ T cells. Likewise, DC-acquired peptide:MHC-II complexes
presented by murine LNSCs to cognate CD4+ T cells not only
failed to promote T cell proliferation but also, in the case of LECs,
induced increased cell death in an antigen-dependent manner.
Frontiers in Immunology | www.frontiersin.org September 2015 | Volume 6 | Article 4469
Hirosue and Dubrot LNSC antigen presentation
Moreover, this process led to CD4+ T cell unresponsiveness to
further restimulation with anti-CD3 and anti-CD28 antibodies
(198). These challenges present a major obstacle in understanding
the relative contributions of acquired peptide:MHC-II complexes
and endogenous MHC-II molecules to CD4+ T cell responses
in vivo.
A recent study described the role of LNSCMHC-II inmaintain-
ing antigen-specific regulatory T cells (Tregs) (134). An elegant
model of LN transplantation was used, where MHC-II-deficient
LN is transplanted into wild-type recipients (Table S1 in Sup-
plementary Material). In this model, the LNSCs remain MHC-II
deficient, while MHC-II-sufficient hematopoietic cells repopulate
the transplanted LN. This local absence of MHC-II expression in
LNSCs was directly correlated with a reduction in Treg numbers.
Importantly, only local Treg numbers were affected, and neither
wild-type transplant control nor endogenous distal LNs exhibited
the same effects.
However, the specific contribution of each LNSC subset
remains to be determined. Indeed, with regards to LEC-restricted
features, such as high levels of PD-L1 expression (156) as well
as non-overlapping PTA expression in LECs, BECs, and FRCs
(146, 152–155), it is likely that each LNSC subtype is capable of
impacting CD4+ T cell outcomes, including Treg development
and differentiation. Moreover, antigen-processing and MHC-II-
mediated antigen presentation by LNSCs still needs to be carefully
dissected, especially in a context where antigen exchange between
neighboring cells has been demonstrated.
In summary, LNSCs possess important roles under physiologi-
cal conditions, and the function of these cells as APCs also appears
to be crucial during ongoing immune responses and inflamma-
tory conditions. The fact that the main stromal cell subsets indeed
upregulate MHC-II expression in a IFN-γ-dependent manner
implies a greater ability of these cells to influence CD4+ T cell
responses in inflamed LNs. In fact, LNSCs have been suggested to
constrain CD4+ T cell expansion after viral challenge (230). The
nature of such effects, however, has not been deeply investigated
and the conclusions remain to be clarified.
Shared Responsibilities
It is striking that many of the mechanisms and functional con-
sequences of antigen presentation are shared across the LNSC
subsets, with the exception of FDCs. The described MHC-I and
II presentation are much the same between FRCs and LECs, and
although less studied, some aspects are also similar in BECs. These
three LNSC subtypes are IFN-γ responsive through expression
of IFN-γ receptor (8). In FRCs and LECs, PD-L1 expression and
lack of co-stimulation seem to be important in their education of
CD8+ T cells. Furthermore, key chemokine and cytokine expres-
sion supporting T cell education is distributed amongst FRCs,
LECs, and BECs, for example, CCL21 expression for attracting
CCR7+ DC and T cells (FRCs, LECs, and BECs) (231), and IL7
for supporting naive T cells (FRCs and LECs) (5, 232–234), and
IL15 for the development and homeostasis for naïve and memory
T cells and other cells (FRCs, BECs, and DN) (235) in the LN.
As the understanding of LNSC antigen presentation deepens, the
shared characteristics between LNSCsmust be reconstructed with
the LN microarchitecture and antigen flow in mind.
Challenges in Studying LNSC Antigen
Presentation
Lack of suitable in vivo models presents a major difficulty in
demonstrating the relative importance of antigen presentation
by LNSC subsets. Directly studying the role of antigen presen-
tation in each LNSC subset, including specific targeting, capture,
and processing of exogenous antigens is not easily accomplished
in vivo (Table S1 in Supplementary Material). While depletion
of hematopoietic cell subtypes is routine and well-established,
ablation of any of the stromal subsets results in a major disruption
of the LNmicroenvironment and organization, and any immuno-
logical effects of LNSC antigen presentation become difficult to
interpret due to experimental artifacts. In this regard, while care
must be taken to exclude the contribution of radioresistant APCs
(134, 236), BM chimeras and LN transplants represent less dras-
tic alternatives that have begun to enable the deconvolution of
hematopoietic from stromal contributions to antigen presenta-
tion. Concerning MHC-II, the CIITA pIV /  mice can be used
as a model for MHC-II abrogation in all non-hematopoietic cells,
including LNSCs (237, 238).
Supposing the antigen presentation can be limited in one LNSC
subtype, another challenge in studying antigen presentation by
LNSCs is the reliance onT cell proliferation as a practical read-out.
In addition to the balance favoring coinhibitory to co-stimulatory
molecules, LNSCs can suppress T cell activation in a contact-
dependent manner (18–20). As T cell proliferation integrates
several outcomes deriving from LNSC and T cell contact, not
limited to antigen peptide:MHC and T cell receptor recognition,
other reporting systems of direct antigen presentation need to be
developed.
What have been rewarding are the models of LNSC subset-
restricted PTA expression (Table S1 in Supplementary Material).
Direct presentation of PTAs by LNSCs has been established largely
by using two animal disease models: inflammatory bowel disease
(146, 152, 239) and autoimmune vitiligo (153, 154, 156, 197, 240),
pairedwithT cells harvested from respective antigen-specific TCR
transgenic mice.
Useful in addressing the challenge of LNSC-restricted antigen
presentation and PTA expression, a number of mouse models
are available in which antigen-presentation machinery can be
knocked out or altered in a stromal cell-specific manner. This
selectivity can be accomplished using the Cre-lox recombination
system, in which target genes marked by loxP recombination
sites are excised by a Cre recombinase enzyme expressed under a
cell-specific promoter (241). Especially in conditionally inducible
form, these transgenic mouse systems present a useful means to
study the immunological roles restricted to each of the stromal
subsets. Examples of this, some of which have already been men-
tioned above, include the CCL19-Cre system for FRC-specific
knockouts (242), and the LYVE-1-Cre and inducible Prox1-
CreERT2 systems for LEC-targeted knockouts (27, 243, 244). As
with any genetic model, there are caveats. For example, using
LYVE-1-Cre, deletion of floxed genes has been observed in some
hematopoietic cells (27). While sparing the major APCs of the
LNs (135), PROX-1, which is essential for lymphatic development
and maintenance (245), have been shown to be expressed by
several other cell types in multiple organs (246). Depending on
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the experimental goals and objectives of a study, both Cre lines
may need to be used as complementary models to evaluate the
immunological outcomes of LEC-specific PTA expression (135).
Podoplanin-Cre has been described to target both LECs andFRCs,
and has contributed to the discovery of a new stromal subset found
in spleen (247). For BECs, Tie2-Cre (248) and Flk1-Cre (249) have
been described (244). It must be noted that both Tie2 and Flk1
are expressed in cells of hematopoietic origin (250, 251), requiring
BM chimeras to limit the effect of Cre recombination to stromal
cells. FDCs have been targeted by using Cd21-Cre (252), and their
developmental origins have been explored by crossing Cd21-Cre
with the Ubow mice in fate-mapping studies (10). Again, it is
notable that Cd21-Cre-mediated deletion was also observed in
other tissues, including the forebrain (253).
In a few cases, these LNSC subset-targeting Cremice have been
crossed with available mouse models carrying floxed MHC-I and
II genes. In fact,MHC-II flox has been successfully usedwithTie2-
Cre to eliminate MHC-II expression in both the hematopoietic
and endothelial lineages, while MHC-II expression remains unaf-
fected in the thymic epithelial cells (250). The naïve CD4+ T cell
numbers were comparable with Cre-negative littermates, while
numbers of Tregs and antigen-experienced cells were significantly
decreased in the knockouts. As for generatingMHC-I conditional
knockouts to be used with Cre systems, mice with β2M floxed
allele can be generated in two steps (254).
Aside from genetically modified animal models, other mecha-
nisms of specifically targeting molecules responsible for antigen
uptake and processing in LNSC subsets have not been actively
explored (255). Once targeting can be achieved, relevant methods
exist to modulate MHC-I antigen presentation, for example, to
inhibit MHC-I loading of peptides using viral inhibitors (128).
Another limitation of drawing any general conclusions for anti-
gen presentation by LNSC derives from the fact that often, LNSC
are defined as bulk populations, based on CD45, gp38 and CD31
expression. Recent papers have delved deeper into nuances of the
LNSC subtypes beyond those defined by these surface markers.
The findings demonstrate the need to further subdivide LNSC
based on their anatomical location, molecular phenotype, and
functional differences (2, 4, 38). For instance, the grossly defined
FRC population contains marginal reticular cells (256), and the
BEC population can be functionally distinguished as being com-
posed of HEVs and capillary endothelial cells (91). Finally, aside
from the recently identified integrin-α7-expressing pericytes (8),
and gp38  FDC (2, 11), the DN fraction (gp38  CD31 ) has
yet to be fully defined. Thus far, no animal models address these
subdivisions.More transgenicmousemodels precisely engineered
(257, 258) to study antigen presentation by LNSC subsets may
become available in the near future.
Alternatively, in vitromodelsmay be used to investigate antigen
presentation in LNSC subtypes. These models present technical
difficulties of their own, especially when using sorted primary
LNSCs. LNSC subtypes are not only defined by surface markers
and cytokine production profiles but also by their biochemical
and biophysical communication with other cells. This interde-
pendence can be indirectly appreciated from transcriptome stud-
ies comparing freshly isolated versus cultured human LECs and
BECs (211), which demonstrated that some key characteristic
gene expression signatures of LECs and BECs were lost following
in vitro culture. Another study compared freshly isolated human
LN FRCs to LN FRCs propagated over 60 days in culture, and
arrived at similar conclusions (259).
Such loss of phenotype may be potentially averted in several
ways. For instance, physiological complexity can be introduced
to existing in vitro LNSC co-culture systems by engineering an
environment that recapitulates physiologically inferred mechan-
ical tension and fluid flow (260). For primary FRCs, CCL21
expression, which is otherwise lost following in vitro culture, was
rescued by growing the cells under conditionsmimicking intersti-
tial flow rates on a 3D composite matrix capable of mechanically
supporting cell tension (261). Moreover, FRC co-culture with
lymphocytes in a semi-3Dnylonmesh promoted the generation of
a robust reticular network structure (15). This further highlights
that LNSC differentiation states and likely antigen-presentation
properties are interdependent on biophysical and biochemical
cues between the neighboring cells and the microenvironment.
Inescapably, the LN architecturemust be reconstructed to grasp
the relevant cell-cell interdependencies in the context of their
LN locations. Established slice cultures (115), development of
organoid cultures and complex in vitro systems (262) improves on
conventional 2D co-culture systems to interrogate LNSC antigen
presentation and immune cell education. Furthermore, dissect-
ing the microanatomical differences of the LNSC subsets using
techniques, such as histo-cytometry (23, 263), which yields multi-
parameter cell marker analysis coupled with anatomical location,
may prove to be informative in understanding the role of LNSC
antigen presentation within the complex coordination of antigen,
DC and T cell interactions (264).
Nevertheless, in vivo models will remain a cornerstone in
understanding LNSC antigen presentation as the biological com-
plexity remains irreproducible in vitro. This includes the dynamics
of the cellularity of the LNSCs, where each LNSC population
differentially expands and contracts during an immune response
upon viral infection and vaccination (94, 230). Two-photon
intravital microscopy has greatly contributed to our understand-
ing of the kinetics of antigen–cell and cell–cell interactions in the
initiation of immune responses in the LN (265). These studies
make use of genetically engineered mouse models, which express
fluorescent proteins in specific stromal cells subsets: for LECs
(246, 266–269), vascular endothelial cells (270, 271), and for LECs
and BECs simultaneously (78, 272) [for review, see Ref. (244)]. So
far, thesemice have generally been used for real-time observations
in organs other than the LN. However, the same mouse models
may greatly contribute to studying the dynamic interactions of
antigens, DCs and T cells with stromal cells (273, 274). By captur-
ing early T cell interactions with antigen-presenting LNSCs, the
issues of using T cell proliferation as a read-out may be avoided.
Much remains to be explored to understand the role of LNSCs
as APCs in both pathological and physiological processes, such
as wound healing, cancer, transplantation, and autoimmunity.
Last but not least, most of the observations of LNSC antigen
presentation have been made in mice, and need to be addressed
in human LNs and diseases. In summary, phenotypic differences
inherent to various LNSC subtypes, their anatomic locations, and
their interactions with surrounding hematopoietic and stromal
cells collectively determine their ability to coordinate antigen
presentation and T cell education. Grasping the contributions of
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individual LNSC subtypes within this complex system remains
elusive due to significant technical hurdles, thus emerging tools,
models, and technologies are likely to be crucial to the elucidation
of key mechanisms.
Relative Contributions of LNSC Antigen
Presentation on Immunological Outcomes
While there is accumulating evidence that LNSCs modulate
peripheral tolerance and the initiation and resolution of immune
responses through both direct and indirect mechanisms, the rela-
tive importance of LNSC versus DC antigen presentation has not
been integrated into a larger model. Several mechanisms of direct
interactions between LNSCs and APCs have been described,
including active antigen transfer and direct sampling of antigens
on LNSCs by APCs. Depending on the model system, hematopoi-
etic APCs are highly important in LNSC-harbored antigen. For
example, in BM chimera studies, there was no antigen-specific
T cell proliferation if LECs are, but the hematopoietic APCs are
not capable of presenting antigen (135). It is certain that DCs
are the dominant actors in antigen presentation and tolerance
induction against peripheral self-antigens (275). In addition to
CD11c+ DCs, extrathymic Aire-expressing cells (eTACs) also
appear to play an important role, namely in peripheral tolerance.
eTACs are a radioresistant CD45lo CD11clo CD11blo MHC-IIhi
PTA-expressing APC of BM origin, which reside in the inter-
follicular region in the LNs (276). eTACs share many features
with antigen-presenting LNSCs, such as similarly low expression
of CD80 and CD86, and high expression of PD-L1. This extends
to their ability to initiate CD8+ T cell deletion (276). They further
deactivate CD4+ T cell responses independently of the enriched
antigen-specific Treg population (277).
Nevertheless, it is clear that the tipping point to initiate an
immune response or to tolerate an antigen is dependent on a fine
balance between antigen presentation by LNSCs or by APCs of
hematopoietic origin.
Initiation and Maintenance of the Immune
Response
The importance of LNSC antigen presentation can be appreciated
in studies of infections in BM chimeric mice. It was shown that
during pathogen infection, non-hematopoietic cells have a notice-
able role in initiating antigen-specific CD4+ T cell responses (230)
and CD8+ T cell proliferation (278, 279). When LNSCs could not
present antigen, the overall clonal expansion was diminished in
several viral infection models, suggesting a role of LNSC antigen
presentation for early clonal CD4+ and CD8+ T cell expansion.
This initial clonal expansion in the CD4+ T cell populations were
10 less than when the antigen is sterile, i.e., non-replicating
(230), which points to the importance of the amount of available
antigen. On the other hand, to sustain the CD8+ T cell expansion,
hematopoietic APCs were reported to be necessary (279).
In these settings, even when focusing on the levels of LNSC
antigen retention and presentation alone, the interpretation is
difficult and does not necessarily correlate with the T cell prolif-
eration response. When compared side by side, the magnitude of
LNSC-primed CD8+ T cell responses differs with the infectious
agent (279). The least T cell proliferation upon LNSC antigen
presentation was seen in Listeria monocytogenes infections (279),
which is thought to mainly target macrophages, DCs, and hep-
atocytes (280) and not be harbored in LECs (97). However, the
greatest effect of LNSC antigen presentation onT cell proliferation
was shown for the LCMVArmstrong strain, which unlike clone 13
of the same virus, does not extensively infect FRCs (95). Rather,
like in an infection with strain WE, the Armstrong infection
results in FRC network destruction and decreased long-term anti-
gen presence in the LN (95, 96). Intermediate contributions of
LNSC antigen presentation were supported by T cell responses
to vaccinia virus, which is archived in LECs (97), and in VSV
infections, both of which infect sessile cells just below the SCS
(281). Thus, systematic analysis must be conducted to understand
how LNSC antigen retention and presentation aid the initiation of
the antigen-specific T cell response.
Distinct T Cell Differentiation States and
Immunological Protection
In light of existing data, an attractive hypothesis is that LNSC
antigen presentation contributes to the generation of diverse T
cell phenotypes in the face of antigen-specific challenge. This
hypothesis is inspired by observations that CD8+ T cells primed
by cross-presenting LSECs, which were previously thought to be
tolerized (282), then were shown to be reactivated under viral
challenge (283). LSECs occupy a large surface area exposed to
blood that carries external food and commensal bacterial antigens
and are known to cross-present exogenous antigens (130, 160,
161). Similar toMHC-I restricted antigen presentation by LNSCs,
antigen cross-presentation by LSECs resulted in tolerized CD8+
T cells, where LSEC PD-L1 expression was important (284, 285).
The surviving LSEC-educated T cells had an antigen-experienced
central memory-like phenotype in secondary lymphoid organs
(283). Furthermore, LSEC-educated T cells could be reactivated
in vitro and in vivo in an antigen-specific manner in the presence
of CD28 and IL12, and they could participate in an antigen-
specific viral challenge with recombinant adenovirus (283).
Given the similarities between LSECs and LNSCs, the obser-
vation that LSEC-educated T cells are not terminally tolerized,
but are primed for reactivation, leads to the question of whether
or not LNSC-educated T cells behave comparably. Earlier,
we described how LNSCs appear to induce a dysfunctionally
activated phenotype in interacting T cells, through their ability
to present antigens but not the co-stimulatory signals required
to induce T cell activation. Like LSEC-educated CD8+ T cells,
LNSC-educated and tolerized CD8+ T cells in the iFABP-tOVA
PTA model were reactivated when challenged with intravenously
injected VSV-OVA (286) (Table S1 in Supplementary Material).
The iFABP-tOVA mouse line with lower PTA expression levels
resolved the infection and retained a cognate CD8+ T cell
population after a VSV-OVA challenge, while the line with
higher antigen expression levels suffered death by T cell mediated
destruction of the PTA-expressing intestinal epithelial cells (286).
These T cells were capable of target lysis, yet unable to secrete
IFN-γ and TNF-α, and resided in inter-epithelial layers (286).
For lack of an existing phenotypic category, the authors called
this phenotype of the LNSC-primed T cell, split-anergy.
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Concluding Remarks
The immunological roles of LNSCs cannot be dissociated from
the structural microarchitecture of the LN, albeit in a much more
nuanced manner than previously appreciated. LNSCs can act at
different levels to promote but also regulate antigen presenta-
tion both directly and indirectly by interacting with APCs and
T cells. Moreover, the interactions and relationships between
the different stromal cells together with DCs (11, 112, 287) are
crucial in framing the immunological roles of LNSCs, which
result in the physical and biochemical modulation of the LN
microenvironment.
The immune system relies heavily on suppression under resting
conditions and during resolution of immune responses. It is not
surprising, then, that more layered and likely redundant cellular
actors and intercellular interactions are involved in suppression
of undesirable immune activation. The LNSC-educated T cells
find a place in the recently articulated adaptation model of
immunity that goes beyond the self/non-self recognition and
danger theory to explain tolerance during an ongoing immune
response: (1) recognition of self/non-self/mimic of self by T cells,
(2) activation of the immune response, and (3) efficacy of the
immune response (288). Within this framework, the efficacy
of the immune response is programed by the expression and
engagement of the sets of adaptation receptor–ligand pairs on the
T cells and their interactingAPCs/LNSCs (for example, PD-1/PD-
L1, other co-stimulatory and coinhibitory molecules, adhesion
molecules, and pattern recognition molecules) (288). At least in
mouse models, LNSCs fulfill the first two requirements: antigen
presentation to T cells, and the initiation of antigen-specific T cell
responses. Furthermore, LNSCs are capable of interacting with
and signaling through distinct sets of adaptation receptors on T
cells from those on hematopoietic APCs (147). Interdependence
of co-stimulatory and coinhibitory pathways generates another
layer of complexity (197).
Antigen presentation in the LN takes place in a wide spectrum
of differently timed and equipped antigen-presenting LNSCs and
hematopoietic APCs, not to mention that the encounter with
lymphocytes is highly influenced by the inflammation responsive
LN microarchitecture. This results in ever-expanding and plastic
phenotypes of antigen-experienced T cells. As more becomes
known about the roles of LNSCs in antigen-specific responses,
their contributions to adaptive immune responsesmust be consid-
ered especially when applying this knowledge to the engineering
of vaccines and immunotherapies.
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